Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Celgene Corporation et al v. Teva Pharmaceuticals USA, Inc.
Case Number:
1:15-cv-01143
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 19, 2016
Teva Settles Drug Patent Row With Celgene, Astellas
Teva Pharmaceuticals has settled allegations that its planned generic version of lymphoma drug Istodax would infringe patents held by Celgene Corp. and Astellas Pharma Inc., according to a joint filing by the companies.
-
December 11, 2015
Celgene, Astellas Sue Teva Over Cancer Drug Patents
Teva Pharmaceuticals' plan to manufacture a generic version of a lymphoma drug would violate patents held by Celgene Corp. and Astellas Pharma Inc., the drugmakers alleged in Delaware federal court Thursday, a year and a half after suing Fresenius over the same patents.